Chr. Hansen

Health Consciousness and Industry Expansion Driving Global Probiotic Market Towards an Estimated Value of $105.27 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023

This report predicts substantial growth in the probiotics sector, estimating the market to reach a staggering USD 105.27 Billion by 2028, up from USD 64.52 Billion in 2022.

Key Points: 
  • This report predicts substantial growth in the probiotics sector, estimating the market to reach a staggering USD 105.27 Billion by 2028, up from USD 64.52 Billion in 2022.
  • Several factors are contributing to the robust expansion of the probiotics market, key among them are:
    Aging Global Population & Health: As the global population ages, the interest in healthy aging and management of age-related health issues intensifies.
  • Probiotics offer considerable potential in promoting gut health, strengthening immune function, and supporting cognitive health.
  • Furthermore, advancements in probiotic strain development that ensure longer shelf life and greater viability are also contributing to market growth.

Global Animal Nutritional Ingredients Markets Report 2018-2022 & 2023-2028 Featuring ADM, Evonik, DSM, BASF, International Flavors & Fragrances, CHR Hansen, Cargill, Novus, Adisseo, & Kemin Industries - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 11, 2023

The Global Animal Nutritional Ingredients Market is expected to generate USD 19.05 billion by the end of 2028, up from USD 14.18 billion in 2021.

Key Points: 
  • The Global Animal Nutritional Ingredients Market is expected to generate USD 19.05 billion by the end of 2028, up from USD 14.18 billion in 2021.
  • During the forecast period, 2023-2028, the Global Animal Nutritional Ingredients market is expected to expand at a CAGR of 6%.
  • However, an increase in animal rearing practices and a substantial rise in the population of domesticated animals have supplemented the growth of the Animal Nutritional Ingredients.
  • Global Animal Nutritional Ingredients Segmentation: By Nutrient Type
    Global Animal Nutritional Ingredients Size, By Minerals, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Vitamins, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Enzymes, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Amino Acids, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Other Nutrients, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Segmentation: By Species
    Global Animal Nutritional Ingredients Size, By Poultry, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Ruminants, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Swine, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Aqua Species, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Other Species, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Segmentation: By Source
    Global Animal Nutritional Ingredients Size, By Corn, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Soybean, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Wheat, By Value, 2018H-2028F (USD Million & CAGR)
    Global Animal Nutritional Ingredients Size, By Other Sources, By Value, 2018H-2028F (USD Million & CAGR)

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

Retrieved on: 
Wednesday, November 10, 2021

Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics, a leading microbiome therapeutics company, announced today a collaboration to manufacture SER-109, Seres lead product candidate for recurrent Clostridioides difficile infection (rCDI).

Key Points: 
  • Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics, a leading microbiome therapeutics company, announced today a collaboration to manufacture SER-109, Seres lead product candidate for recurrent Clostridioides difficile infection (rCDI).
  • Eric Shaff, CEO, Seres, added: Our mission at Seres is to transform the lives of patients worldwide with revolutionary microbiome therapeutics.
  • The agreement between Bacthera and Seres Therapeutics aims to expand upon Seres initial commercial manufacturing supply chain.
  • In addition to Seres existing manufacturing infrastructure, the collaboration with Bacthera will expand the commercial production capacities of SER-109 and provide supply support.

Global Eubiotics Market Outlook 2021-2028: Eubiotics as An Alternative to Antibiotics - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 30, 2021

The global eubiotics market is forecast to advance at a CAGR of 7.43% over the registered period from 2021 to 2028.

Key Points: 
  • The global eubiotics market is forecast to advance at a CAGR of 7.43% over the registered period from 2021 to 2028.
  • The global eubiotics market comprises the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.
  • The Asia-Pacific is expected to witness the fastest growth rate in the eubiotics market over the estimated phase.
  • Therefore, these factors are majorly supplementing the development of the eubiotics market over the forecasted period across the APAC region.